Fumex F, Coumaros D, Napoleon B, Barthet M, Laugier R, Yzet T, Le Sidaner A, Desurmont P, Lamouliatte H, Letard J-C, Canard J-M, Prat F, Rey J-F, Ponchon T
Deparment of Gastroenterology, North Hospital, University of Saint-Etienne, France.
Endoscopy. 2006 Aug;38(8):787-92. doi: 10.1055/s-2006-944515.
Endoscopic biliary stenting is now a well-established treatment method in patients with unresectable malignant biliary obstruction. Despite advances with metal stents, the problem of stent occlusion has not yet been resolved. Covered metal stents could reduce the occlusion rate by preventing tumor ingrowth, but have not been well evaluated. A prospective multicenter study was therefore conducted to evaluate the efficacy and disadvantages of covered Wallstents.
Covered Wallstents were implanted endoscopically in 62 patients with inoperable distal malignant biliary obstruction. Complications, stent patency, and patient survival were analyzed.
Stent insertion was achieved in 61 of the 62 patients (98.4 %). Procedure-related complications were observed in four patients, consisting of minor pancreatitis (n = 2) and abdominal pain due to stent expansion (n = 2). There was no procedure-related mortality. Seven patients died too early for proper assessment, so that a total of 54 patients were ultimately evaluated. Stent dysfunction occurred in 17 of the 54 patients (31.5 %). The reasons for dysfunction were proximal tumor overgrowth (n = 5), migration (n = 3), lithiasis or food impaction (n = 3), cholangitis without the need for a repeat biliary intervention (n = 5), and unknown (n = 1). The median period of stent patency was 142 days. No tumor ingrowth was observed. Acute cholecystitis was diagnosed in five patients (10 %) and was responsible for one death. Three stents were successfully removed.
Covered biliary metal stents are effective for the drainage of distal malignant biliary obstruction, with a dysfunction rate apparently similar to that of uncovered stents. However, the risk of acute cholecystitis appears to be a major concern with this type of stent in patients with gallbladder in situ. Further comparative studies are needed.
内镜下胆管支架置入术现已成为不可切除恶性胆管梗阻患者的一种成熟治疗方法。尽管金属支架有了进展,但支架阻塞问题尚未得到解决。覆膜金属支架可通过防止肿瘤长入来降低阻塞率,但尚未得到充分评估。因此,开展了一项前瞻性多中心研究,以评估覆膜Wallstent支架的疗效和缺点。
对62例无法手术的远端恶性胆管梗阻患者进行内镜下覆膜Wallstent支架置入术。分析并发症、支架通畅情况和患者生存率。
62例患者中有61例成功置入支架(98.4%)。4例患者出现与手术相关的并发症,包括轻度胰腺炎(2例)和支架扩张引起的腹痛(2例)。无手术相关死亡。7例患者过早死亡,无法进行适当评估,因此最终共评估了54例患者。54例患者中有17例(31.5%)出现支架功能障碍。功能障碍的原因包括近端肿瘤过度生长(5例)、移位(3例)、结石或食物嵌塞(3例)、无需重复胆管介入的胆管炎(5例)以及原因不明(1例)。支架通畅的中位时间为142天。未观察到肿瘤长入。5例患者(10%)被诊断为急性胆囊炎,其中1例死亡。成功取出3个支架。
覆膜胆管金属支架对远端恶性胆管梗阻引流有效,功能障碍发生率明显与未覆膜支架相似。然而,对于原位胆囊患者,急性胆囊炎风险似乎是这类支架的一个主要问题。需要进一步的比较研究。